Lumira Ventures Invests in Nocion Therapeutics to Advance Chronic Cough Treatment

Lumira Ventures announced a significant investment in Nocion Therapeutics, a company focusing on the development of small molecule charged sodium channel blockers, known as Nocions. These compounds aim to treat conditions like cough, itch, and pain by silencing activated nociceptors. The investment will fund a Phase 2b study for Taplucanium Dry Powder, targeting chronic cough treatment.

Lu Han from Lumira Ventures expressed excitement about Taplucanium's specific mechanism and its potential for treating chronic cough sufferers who currently have limited options. Nocion Therapeutics has completed a Series B financing round led by Arkin Bio Capital and Monograph Capital, raising $70 million with Lumira Ventures and other investors' support.

Benjamin Rovinski of Lumira Ventures highlighted their commitment to a strong management team in Nocion, aiming to address significant unmet medical needs. Additionally, with Lumira Ventures joining Nocion's Board as an observer, the partnership is poised to advance Taplucanium towards Phase 3 readiness, aiming to offer a transformative treatment solution for chronic cough patients rapidly.